AU2006271308B2 - Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS - Google Patents

Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS Download PDF

Info

Publication number
AU2006271308B2
AU2006271308B2 AU2006271308A AU2006271308A AU2006271308B2 AU 2006271308 B2 AU2006271308 B2 AU 2006271308B2 AU 2006271308 A AU2006271308 A AU 2006271308A AU 2006271308 A AU2006271308 A AU 2006271308A AU 2006271308 B2 AU2006271308 B2 AU 2006271308B2
Authority
AU
Australia
Prior art keywords
bmp
tumor
cells
cell
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006271308A
Other languages
English (en)
Other versions
AU2006271308A1 (en
Inventor
Brent Allan Reynolds
Angelo Luigi Vescovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEMGEN SpA
Original Assignee
STEMGEN SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEMGEN SpA filed Critical STEMGEN SpA
Publication of AU2006271308A1 publication Critical patent/AU2006271308A1/en
Priority to AU2012202157A priority Critical patent/AU2012202157B2/en
Application granted granted Critical
Publication of AU2006271308B2 publication Critical patent/AU2006271308B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2006271308A 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS Active AU2006271308B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202157A AU2012202157B2 (en) 2005-07-19 2012-04-13 Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19
US60/700,859 2005-07-19
PCT/IB2006/002296 WO2007010394A2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202157A Division AU2012202157B2 (en) 2005-07-19 2012-04-13 Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS

Publications (2)

Publication Number Publication Date
AU2006271308A1 AU2006271308A1 (en) 2007-01-25
AU2006271308B2 true AU2006271308B2 (en) 2012-12-20

Family

ID=37420973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006271308A Active AU2006271308B2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS

Country Status (13)

Country Link
US (2) US9220756B2 (cg-RX-API-DMAC7.html)
EP (2) EP3117833B1 (cg-RX-API-DMAC7.html)
JP (3) JP5189977B2 (cg-RX-API-DMAC7.html)
KR (2) KR101311061B1 (cg-RX-API-DMAC7.html)
AU (1) AU2006271308B2 (cg-RX-API-DMAC7.html)
CA (2) CA2615491C (cg-RX-API-DMAC7.html)
DK (2) DK1904093T3 (cg-RX-API-DMAC7.html)
ES (2) ES2686093T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181379T1 (cg-RX-API-DMAC7.html)
HU (2) HUE040063T2 (cg-RX-API-DMAC7.html)
NZ (2) NZ598031A (cg-RX-API-DMAC7.html)
PL (2) PL3117833T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007010394A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010394A2 (en) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
ATE526984T1 (de) 2008-02-13 2011-10-15 Dkfz Krebsforschungszentrum Knochen-morphogenetische proteine zur verwendung zur behandlung und prävention von neuroblastomen
JP7056932B2 (ja) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用
AU2016324971A1 (en) * 2015-09-17 2018-04-19 Histide Ag Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrierfor converting a neoplastic cell into a non-neoplastic cell and uses thereof
HRP20211627T1 (hr) * 2015-09-17 2022-02-04 Histide Ag Farmaceutski pripravak koji se sastoji od agonista receptora čimbenika rasta i proteina inhibitora adhezije za pretvaranje neoplastične stanice u neneoplastičnu stanicu i njegova upotreba
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
JP6890835B2 (ja) * 2015-09-17 2021-06-18 ヒスタイド アクツィエンゲゼルシャフト 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
WO2020138503A1 (ja) * 2018-12-28 2020-07-02 国立大学法人 東京大学 神経膠腫の治療および予防剤、脳腫瘍の悪性度のマーカーおよび脳腫瘍の予後マーカー、脳腫瘍の悪性度および予後の判定方法並びに腫瘍増殖を抑制する抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013985A1 (en) * 1990-03-05 1991-09-19 John Kaye Heath Leukaemia inhibitory factor
WO2000029012A2 (en) * 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
DE69231726D1 (de) * 1991-12-24 2001-04-12 Amrad Corp Ltd Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
CA2187902A1 (en) * 1994-04-29 1995-11-09 Peter Ten Dijke Morphogenic protein-specific cell surface receptors and uses therefor
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6020141A (en) 1996-05-09 2000-02-01 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization
CA2393159C (en) * 1999-12-06 2010-04-20 Paul Calabresi Methods of treating tumors
EP1267911A4 (en) * 2000-03-03 2004-04-21 Amrad Corp Ltd TREATMENT METHOD
CA2537960C (en) 2003-09-12 2012-01-10 Stemcell Technologies Inc. Neural colony forming assay
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
WO2005057172A2 (en) * 2003-12-05 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
EP2319526A1 (en) * 2004-06-17 2011-05-11 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
WO2007010394A2 (en) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
US10130590B2 (en) * 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013985A1 (en) * 1990-03-05 1991-09-19 John Kaye Heath Leukaemia inhibitory factor
WO2000029012A2 (en) * 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Andrews, P. et al. 1994 Laboratory Investigation, vol. 71, no. 2, pp.243-251 *
Ro, T. et al. 2004 Oncogene, vol. 23, pp. 3024-3032 *
Soda, H. et al. 1998 Anti-Cancer Drugs, vol. 9, no. 4, pp. 327-331 *
Ying, Q-L. et al. 2003 Cell, vol. 115, pp. 281-292 *

Also Published As

Publication number Publication date
CA2790675A1 (en) 2007-01-25
PL3117833T3 (pl) 2019-06-28
HRP20181379T1 (hr) 2018-11-16
WO2007010394A2 (en) 2007-01-25
ES2686093T3 (es) 2018-10-16
HUE042197T2 (hu) 2019-06-28
JP5891068B2 (ja) 2016-03-22
KR101311061B1 (ko) 2013-09-25
EP3117833B1 (en) 2019-01-23
NZ598031A (en) 2013-11-29
JP5189977B2 (ja) 2013-04-24
US9220756B2 (en) 2015-12-29
ES2710601T3 (es) 2019-04-26
US20100167999A1 (en) 2010-07-01
JP2012107063A (ja) 2012-06-07
US9737589B2 (en) 2017-08-22
KR20120125990A (ko) 2012-11-19
EP1904093B1 (en) 2018-06-13
EP1904093A2 (en) 2008-04-02
DK3117833T3 (en) 2019-03-18
PL1904093T3 (pl) 2018-12-31
US20160228511A1 (en) 2016-08-11
HUE040063T2 (hu) 2019-02-28
JP2015057452A (ja) 2015-03-26
DK1904093T3 (en) 2018-09-03
KR101338533B1 (ko) 2013-12-12
CA2615491C (en) 2016-11-29
CA2615491A1 (en) 2007-01-25
KR20080082595A (ko) 2008-09-11
JP2009502771A (ja) 2009-01-29
WO2007010394A3 (en) 2007-08-30
CA2790675C (en) 2016-12-20
AU2006271308A1 (en) 2007-01-25
EP3117833A1 (en) 2017-01-18
NZ565172A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
US9737589B2 (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPs
Fang et al. TGF-β1-elevated TRPM7 channel regulates collagen expression in hepatic stellate cells via TGF-β1/Smad pathway
JP6523910B2 (ja) 腫瘍幹細胞におけるｅｐｈ受容体発現
Wei et al. Deficiency of unc-51 like kinase 1 (Ulk1) protects against mice traumatic brain injury (TBI) by suppression of p38 and JNK pathway
Li et al. Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway
Berger et al. Co-regulated decrease of Neurokinin-1 receptor and Hemokinin-1 gene expression in monocytes and macrophages after activation with pro-inflammatory cytokines
AU2012202157B2 (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
HK1233494A (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1233494A1 (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1233494B (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1117414A (en) Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
HK1117414B (en) Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
Frazer et al. BMP antagonist Gremlin 2 regulates hippocampal neurogenesis and is associated with seizure susceptibility and anxiety
Battistello PEMFs and cerebral ischemia: the pathways behind their beneficial effects
Almale del Barrio Crosstalk between HGF and TGF-ß signaling pathways in adult liver progenitor cells and hepatocellular carcinoma cells
US10233240B1 (en) Methods for treating cholestatic liver fibrosis
Dropmann TGF-β2 abundance in mice and men: A successful anti-TGF-β2 strategy in biliary-derived liver disease
Pierre et al. Original Research Article J. cell. Physiol
Yang The functions of RecQ protein-like 4 and high mobility group box 1 in osteoblast-like cells
Boelte The role of Rgs2 in hematopoiesis and myeloid derived suppressor cells in cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)